- Home
- YMAB vs JRS Comparison
YMAB vs JRS Comparison
Compare YMAB & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- JRS
- Stock Information
- Founded
- YMAB 2015
- JRS 2001
- Country
- YMAB United States
- JRS United States
- Employees
- YMAB N/A
- JRS N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- JRS Finance/Investors Services
- Sector
- YMAB Health Care
- JRS Finance
- Exchange
- YMAB Nasdaq
- JRS Nasdaq
- Market Cap
- YMAB 270.5M
- JRS 236.9M
- IPO Year
- YMAB 2018
- JRS N/A
- Fundamental
- Price
- YMAB $4.43
- JRS $8.23
- Analyst Decision
- YMAB Buy
- JRS
- Analyst Count
- YMAB 11
- JRS 0
- Target Price
- YMAB $18.73
- JRS N/A
- AVG Volume (30 Days)
- YMAB 328.7K
- JRS 86.6K
- Earning Date
- YMAB 03-04-2025
- JRS 01-01-0001
- Dividend Yield
- YMAB N/A
- JRS 8.87%
- EPS Growth
- YMAB N/A
- JRS N/A
- EPS
- YMAB N/A
- JRS N/A
- Revenue
- YMAB $87,685,000.00
- JRS N/A
- Revenue This Year
- YMAB $20.07
- JRS N/A
- Revenue Next Year
- YMAB $8.76
- JRS N/A
- P/E Ratio
- YMAB N/A
- JRS N/A
- Revenue Growth
- YMAB 3.38
- JRS N/A
- 52 Week Low
- YMAB $4.25
- JRS $5.95
- 52 Week High
- YMAB $17.78
- JRS $8.00
- Technical
- Relative Strength Index (RSI)
- YMAB 34.59
- JRS 42.90
- Support Level
- YMAB $4.65
- JRS $8.04
- Resistance Level
- YMAB $5.25
- JRS $8.21
- Average True Range (ATR)
- YMAB 0.30
- JRS 0.11
- MACD
- YMAB 0.03
- JRS -0.00
- Stochastic Oscillator
- YMAB 6.32
- JRS 46.34
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.